Other retinal disorders in diseases classified elsewhere

H7_RETINODISINOTH

eye disease: A non-neoplastic or neoplastic disorder that affects the eye. Representative examples include conjunctivitis, glaucoma, cataract, conjunctival squamous cell carcinoma, uveal melanoma, and retinoblastoma. [NCIt:C26767]

Suggest a new description

Endpoint definition

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

557745

1. Apply sex-specific rule

None

557745

2. Check conditions

None

557745

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

2 out of 7 registries used, show all original rules.

93

4. Check minimum number of events

None

93

5. Include endpoints

None

93

6. Filter based on genotype QC (FinnGen only)

80

Control definitions (FinnGen only)

Control exclude
H7_CHOROIDRETINA

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2

Case counts by codes

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 574 264 305
Only index persons 475 225 250
Unadjusted period prevalence (%)
Whole population 0.01 0.01 0.01
Only index persons 0.01 0.01 0.01
Median age at first event (years)
Whole population 73.40 75.61 71.43
Only index persons 71.89 74.19 69.82

-FinnGen-

Key figures

All Female Male
Number of individuals 80 25 55
Unadjusted period prevalence (%) 0.02 0.01 0.03
Median age at first event (years) 70.54 70.43 70.59

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
84
Matched controls
840
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H36.8*I70.8
ICD-10 Finland
Atherosclerotic retinopathy
+∞
92.6
71
*
XCK10
NOMESCO Finland
Photography of fundus of eye
14.3
28.0
31
33
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
10.3
25.7
41
71
CKC12
NOMESCO Finland
Photocoagulation of retina
+∞
25.3
23
*
I65.2
ICD-10 Finland
Occlusion and stenosis of carotid artery
43.3
22.3
27
9
Z3229
NOMESCO Finland
Other healthcare associate professional
10.0
19.5
27
38
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
13.4
14.6
26
27
Z2221
NOMESCO Finland
Medical doctor
5.6
13.8
42
128
XCW99
NOMESCO Finland
Other investigative procedure of eye
12.4
13.1
24
26
Z3231
NOMESCO Finland
Registered nurse
5.0
12.2
44
152
XPX99
NOMESCO Finland
Other diagnostic examination of periferal vessel
6.7
12.1
23
45
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
5.3
11.8
33
92
I70.8
ICD-10 Finland
Atherosclerosis of other arteries
138.2
11.7
12
*
CKD05
NOMESCO Finland
Puncture of vitreous body with injection of medication
138.2
11.7
12
*
I25.1
ICD-10 Finland
Atherosclerotic heart disease
4.7
11.5
46
171
PAF14
NOMESCO Finland
Thrombendarterectomy of internal carotid artery
21.5
11.2
16
9
B01AC04
ATC
clopidogrel; oral
4.7
11.1
39
130
PG1DE
NOMESCO Finland
Other extensive ultrasound examination of artery
14.9
11.0
18
15
Z01.0
ICD-10 Finland
Examination of eyes and vision
5.2
10.6
28
74
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
4.2
9.1
34
116
PA6BD
NOMESCO Finland
Extensive CT of neck arteries
16.5
9.1
14
10
XF400
NOMESCO Finland
ECG with 12 standard connections
4.4
9.0
30
94
I70.9
ICD-10 Finland
Generalized and unspecified atherosclerosis
13.7
9.0
15
13
A10AC01
ATC
insulin (human); parenteral
8.1
8.9
20
31
PA6DE
NOMESCO Finland
Neck artery ultrasound examination with Doppler method
11.3
8.7
16
17
R4110
NOMESCO Finland
Physiotherapy
4.0
8.7
39
151
H36.8
ICD-10 Finland
Other retinal disorders in diseases classified elsewhere
+∞
8.5
8
*
PAN14
NOMESCO Finland
Plastic repair of arteries internal carotid artery
37.3
8.3
10
*
L97
ICD-10 Finland
Ulcer of lower limb, not elsewhere classified
10.9
7.6
14
15
ZXA00
NOMESCO Finland
Right side
3.7
7.6
36
143
H34.8
ICD-10 Finland
Other retinal vascular occlusions
87.5
7.5
8
*
WX002
NOMESCO Finland
Sedation and analgesia
4.1
7.5
26
83
C10AA01
ATC
simvastatin; oral
3.7
7.5
56
297
H35.0
ICD-10 Finland
Background retinopathy and retinal vascular changes
+∞
7.4
7
*
H3601, E113,
ICD-10 Finland
+∞
7.4
7
*
E10.7
ICD-10 Finland
Type 1 diabetes mellitus, With multiple complications
33.2
7.3
9
*
ZXD10
NOMESCO Finland
Scheduled procedure
3.4
7.0
45
214
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
8.0
6.9
15
22
ZXA10
NOMESCO Finland
Bilateral
3.8
6.8
27
94
103
Kela drug reimbursment
Diabetes, insulin-treated
3.3
6.6
39
175
215
Kela drug reimbursment
Diabetes, non-insulin-treated
3.4
6.6
33
134
I63.9
ICD-10 Finland
Cerebral infarction, unspecified
3.9
6.6
24
79
CK2L4
NOMESCO Finland
Wide-field/panoramic imaging of ocular fundus
75.3
6.5
7
*
H36.01
ICD-10 Finland
Diabetic maculopathy
+∞
6.3
6
*
H21.1
ICD-10 Finland
Other vascular disorders of iris and ciliary body
+∞
6.3
6
*
CKC20
NOMESCO Finland
Cryopexy of undetached retina
+∞
6.3
6
*
XCD20
NOMESCO Finland
Photoangiography of eye
+∞
6.3
6
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.2
6.3
52
282
A10AB05
ATC
insulin aspart; parenteral
6.0
6.3
17
34
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
3.4
6.3
30
118
E11.7
ICD-10 Finland
Type 2 diabetes mellitus, with multiple complications
6.1
6.1
16
31
ZXE00
NOMESCO Finland
One hour or less
3.1
6.1
43
213
NHQ40
NOMESCO Finland
Amputation of toe
16.6
6.0
9
6
A10AA02, ,
ATC
16.6
6.0
9
6

LabWAS

OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
45
150
5.31
13.22
8.5
4.5
86.44
85.49
%
0.09
45
145
43
211
3.13
6.19
4.7
2.5
—
—
—
0
0
21
68
3.78
5.83
20.8
4.6
1.67
2.19
mmol/l
0.30
21
53
21
71
3.61
5.45
12.0
4.5
7.36
7.38
ph
0.96
13
46
13
24
6.20
5.16
2.5
2.3
319.00
397.20
ug/l
0.14
13
24
23
87
3.26
5.00
20.8
7.5
1.23
1.06
mmol/l
1.01
23
79
19
66
3.43
4.70
27.9
10.3
—
—
—
0
0
39
204
2.70
4.70
9.0
4.8
7.40
7.40
ph
0.38
27
151
16
51
3.64
4.48
20.2
8.1
24.92
24.84
mmol/l
0.04
16
51
19
68
3.32
4.48
3.4
1.6
—
—
—
0
0
24
100
2.96
4.39
19.0
7.2
104.04
105.06
mmol/l
0.44
24
100
16
52
3.57
4.35
4.0
1.7
—
—
—
0
0
48
286
2.58
4.35
2.9
2.0
94.50
92.99
pmol/l
0.07
22
154
53
333
2.60
4.27
20.8
7.2
1.19
1.21
mmol/l
1.19
48
288
39
216
2.50
4.06
8.2
4.9
—
—
—
0
0
16
58
3.17
3.66
3.8
1.5
—
—
—
0
0
23
108
2.56
3.29
6.1
3.2
2.18
0.78
e6/l
0.32
11
58
14
50
3.16
3.27
19.8
10.0
0.62
0.66
%
0.19
14
50
14
50
3.16
3.27
19.8
9.5
1.94
1.38
%
0.33
14
50
45
291
2.18
3.05
7.2
2.8
—
—
estimate
—
0
0
20
91
2.57
3.03
15.0
7.4
5.30
5.06
kpa
0.53
20
85
20
91
2.57
3.03
15.2
7.4
11.22
10.99
kpa
0.09
20
86
20
91
2.57
3.03
15.3
7.5
7.34
7.41
ph
—
8
52
5
5
10.51
3.01
1.0
1.2
—
—
—
0
0
11
33
3.68
2.94
2.3
1.6
—
—
—
0
0
36
219
2.13
2.79
12.1
5.2
—
—
—
0
0
17
75
2.59
2.73
3.6
1.9
—
—
—
0
0
10
30
3.64
2.71
2.2
2.1
—
—
—
0
0
49
340
2.06
2.63
18.7
14.8
1.20
1.30
inr
0.74
43
288
6
11
5.78
2.59
2.3
1.4
—
—
—
0
0
9
210
0.36
2.55
3.9
3.3
—
—
—
0
0
35
224
1.96
2.28
4.6
3.2
7.23
7.99
mmol/l
0.51
27
190
47
333
1.93
2.26
12.8
6.3
0.23
0.20
e9/l
0.69
40
284
39
260
1.93
2.25
6.1
4.1
21.04
51.75
e6/l
1.09
27
192
27
160
2.01
2.17
1.4
1.3
—
—
—
0
0
46
331
1.86
2.05
11.5
6.0
2.82
1.82
e9/l
0.63
40
289
49
360
1.87
2.04
15.8
9.6
4.48
4.35
e9/l
0.11
40
307
30
189
1.91
2.01
4.6
3.4
—
—
estimate
—
0
0
45
324
1.84
1.98
11.8
5.8
0.67
0.59
e9/l
0.87
38
273
45
325
1.83
1.95
11.7
5.9
0.05
0.04
e9/l
0.85
38
273
31
200
1.87
1.92
6.0
3.4
0.39
0.32
e6/l
0.11
24
147
40
280
1.82
1.91
26.4
12.3
0.05
0.00
e9/l
0.48
31
229
34
228
1.83
1.85
5.8
3.8
44.42
11.74
mg/mmol
0.63
19
151
33
220
1.82
1.83
4.9
3.2
199.24
64.59
mg/l
0.69
24
152
33
234
1.68
1.42
2.2
2.2
—
—
—
0
0
50
396
1.65
1.39
14.3
5.1
7.61
6.75
mmol/l
1.39
50
375
12
63
2.06
1.30
1.7
1.5
—
—
—
0
0
17
102
1.84
1.28
4.4
1.8
—
—
—
0
0
10
50
2.14
1.22
1.1
3.5
65.97
66.22
g/l
—
10
45
32
236
1.57
1.14
6.1
3.5
134.71
296.25
e6/l
0.23
25
182
11
59
1.99
1.13
1.4
1.3
—
—
—
0
0
7
34
2.15
1.05
1.3
2.0
1.00
1.00
g/l
—
7
28
7
35
2.09
1.02
16.9
2.7
0.61
0.64
%
—
7
35
28
206
1.54
0.99
14.8
5.7
—
—
—
0
0
7
36
2.03
0.99
16.9
2.7
1.11
1.27
%
—
7
36
16
235
0.61
0.98
2.2
1.9
1.37
1.28
mmol/l
0.30
16
188
6
28
2.23
0.93
1.3
1.1
—
—
—
0
0
8
42
2.00
0.92
1.0
1.2
—
—
—
0
0
6
31
2.01
0.86
1.7
1.2
—
—
—
0
0
16
108
1.59
0.81
1.3
1.8
2.48
3.29
g/l
—
10
59
12
75
1.70
0.80
1.4
1.3
—
—
—
0
0
12
75
1.70
0.80
3.3
4.0
3.02
65.57
ug/l
0.62
12
66
20
143
1.52
0.80
5.6
3.2
520.95
538.80
mosm/kgh2o
0.23
20
123
23
172
1.46
0.74
2.7
2.9
7.36
3.18
e6/l
0.80
23
151
32
255
1.41
0.74
4.3
4.0
6.14
6.22
ph
0.11
11
144
28
219
1.42
0.72
3.9
3.1
2.36
2.35
mmol/l
0.06
28
197
5
27
1.90
0.69
1.8
1.8
—
—
—
0
0
7
43
1.68
0.68
1.7
3.0
11.69
10.68
g/l
—
7
36
5
29
1.77
0.65
6.0
2.7
—
—
—
0
0
24
189
1.38
0.58
4.5
3.5
—
—
—
0
0
51
451
1.33
0.58
3.5
3.9
14.60
15.02
pmol/l
0.44
43
407
12
83
1.52
0.55
1.5
1.3
—
—
—
0
0
17
127
1.42
0.55
1.8
1.6
675.30
1190.89
nmol/l
—
10
96
60
553
1.30
0.44
5.1
4.8
1.65
1.99
mu/l
2.16
54
495
10
70
1.49
0.44
1.3
1.2
—
—
—
0
0
0
19
0.00
0.39
0.0
6.3
—
39.25
—
0
12
20
236
0.80
0.32
6.1
3.9
—
—
—
0
0
10
128
0.75
0.29
7.2
5.7
—
—
—
0
0
47
433
1.19
0.29
6.4
5.0
—
1250.50
—
0
10
5
39
1.30
0.23
1.2
2.9
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
6
48
1.27
0.21
1.2
3.0
—
—
—
0
0
6
48
1.27
0.21
1.8
1.6
—
—
—
0
0
6
50
1.22
0.20
35.2
4.1
1.18
1.22
mmol/l
—
6
43
58
553
1.16
0.20
5.5
4.6
1.41
1.29
mmol/l
0.85
52
505
64
616
1.16
0.18
36.6
15.6
—
—
—
0
0
13
149
0.85
0.15
2.5
5.0
1.02
1.02
kg/l
—
7
109
62
601
1.12
0.12
8.1
6.0
2.18
2.61
mmol/l
4.46
56
549
21
196
1.10
0.08
3.1
3.2
0.47
0.71
ug/l
1.14
14
129
6
74
0.80
0.08
1.5
2.2
71.83
117.08
ug/g
—
6
62
35
335
1.08
0.08
4.5
4.2
0.00
0.00
estimate
—
5
74
33
343
0.94
0.06
4.5
5.4
29.37
2.26
ug/l
0.47
28
304
64
629
1.07
0.05
50.9
21.7
139.08
139.64
mmol/l
0.74
64
617
64
630
1.07
0.04
54.6
21.8
4.08
4.02
mmol/l
0.67
64
618
58
590
0.95
0.04
7.1
5.5
7.02
6.08
mmol/l
2.11
50
535
35
341
1.05
0.03
4.5
4.3
0.00
21.95
estimate
—
5
74
29
284
1.03
0.00
5.4
4.4
211.08
40.91
ng/l
0.66
24
211
58
581
0.99
0.00
6.3
5.2
1.20
1.40
mmol/l
3.34
52
533
58
583
0.98
0.00
6.3
5.3
3.86
4.46
mmol/l
5.92
53
537
64
645
0.97
0.00
47.7
23.5
121.56
85.45
umol/l
1.37
64
637
0
8
0.00
-0.00
0.0
3.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
4.0
—
295.12
—
0
8
0
6
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.8
—
1.58
—
0
8
0
5
0.00
-0.00
0.0
3.6
—
6.82
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
6.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
193.50
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.8
—
1.09
—
0
9
0
9
0.00
-0.00
0.0
3.0
—
3.46
—
0
9

Mortality – FinRegistry

Association

Association between endpoint H7_RETINODISINOTH and mortality.

Females

Parameter HR [95% CI] p-value
H7_RETINODISINOTH 2.022 [1.43, 2.87] < 0.001
Birth year 0.996 [0.99, 1.0] 0.309

During the follow-up period (1.1.1998 — 31.12.2019), 112 out of 224 females with H7_RETINODISINOTH died.

Males

Parameter HR [95% CI] p-value
H7_RETINODISINOTH 3.116 [2.09, 4.64] < 0.001
Birth year 0.988 [0.98, 1.0] 0.013

During the follow-up period (1.1.1998 — 31.12.2019), 158 out of 276 males with H7_RETINODISINOTH died.

Mortality risk

Mortality risk for people of age

years, who have H7_RETINODISINOTH.

N-year risk Females Males
1 0.201% 0.653%
5 1.355% 3.505%
10 3.207% 8.552%
15 5.726% 16.384%
20 10.189% 26.337%

Relationships between endpoints

Index endpoint: H7_RETINODISINOTH – Other retinal disorders in diseases classified elsewhere

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data